D Boral Capital Upgrades Turn Therapeutics (NASDAQ:TTRX) to Strong-Buy

Turn Therapeutics (NASDAQ:TTRX) was upgraded by stock analysts at D Boral Capital to a “strong-buy” rating in a report released on Monday, Marketbeat.com reports.

Separately, D. Boral Capital assumed coverage on shares of Turn Therapeutics in a research report on Monday. They issued a “buy” rating and a $8.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. According to MarketBeat.com, Turn Therapeutics has an average rating of “Strong Buy” and an average target price of $8.00.

Turn Therapeutics Price Performance

Shares of TTRX opened at $3.71 on Monday. The stock has a 50 day simple moving average of $3.57. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) EPS for the quarter.

Insiders Place Their Bets

In other news, insider Abraham Chesed bought 14,286 shares of Turn Therapeutics stock in a transaction that occurred on Thursday, October 23rd. The stock was bought at an average price of $4.60 per share, for a total transaction of $65,715.60. Following the purchase, the insider directly owned 1,447,268 shares of the company’s stock, valued at approximately $6,657,432.80. The trade was a 1.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Golden purchased 20,532 shares of the company’s stock in a transaction on Friday, November 21st. The shares were purchased at an average price of $2.87 per share, for a total transaction of $58,926.84. Following the purchase, the director owned 50,734 shares in the company, valued at approximately $145,606.58. The trade was a 67.98% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 52,136 shares of company stock valued at $183,463 in the last 90 days.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.